SA
BCRX icon

Sanctuary Advisors’s BioCryst Pharmaceuticals BCRX Stock Holding History

Sanctuary Advisors’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$587K Buy
58,673
+2,995
+5% +$27.1K ﹤0.01% 1859
2026
Q1 		$530K Sell
55,678
-2,893
-5% -$22.5K ﹤0.01% 1738
2025
Q4 		$457K Buy
58,571
+15,544
+36% +$112K ﹤0.01% 1781
2025
Q3 		$327K Sell
43,027
-1,137
-3% -$9.47K ﹤0.01% 1951
2025
Q2 		$396K Buy
44,164
+649
+1% +$6.04K ﹤0.01% 1755
2025
Q1 		$326K Sell
43,515
-1,272
-3% -$10.3K ﹤0.01% 1741
2024
Q4 		$352K Sell
44,787
-2,602
-5% -$19.8K ﹤0.01% 1898
2024
Q3 		$360K Buy
47,389
+20,818
+78% +$158K ﹤0.01% 1894
2024
Q2 		$111K Buy
+26,571
New +$147K ﹤0.01% 2249

Other funds holding BCRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Sanctuary Advisors's BCRX Position: Q2 2026 in Review

Sanctuary Advisors increased its BioCryst Pharmaceuticals (BCRX) stake by 5.4% in Q2 2026, buying an estimated $27.1K and bringing the position to 58,673 shares worth $587K. The position accounts for ﹤0.01% of the portfolio, ranked #1859.

Sanctuary Advisors first reported a position in BCRX in Q2 2024 and has held it in 9 quarters since. 318 funds tracked by Wall St. Rank hold BCRX as of Q2 2026.

  • Sanctuary Advisors held 58,673 shares of BioCryst Pharmaceuticals worth $587K as of Q2 2026.
  • Sanctuary Advisors bought 2,995 BioCryst Pharmaceuticals shares in Q2 2026, an estimated $27.1K.
  • BioCryst Pharmaceuticals made up ﹤0.01% of Sanctuary Advisors's portfolio in Q2 2026, its #1859 holding.
  • Sanctuary Advisors first reported a position in BioCryst Pharmaceuticals in Q2 2024 and has held it in 9 quarters since.
  • 318 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2026.

Based on Sanctuary Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.